Lactate induces PD-L1 in HRASG12V-positive oropharyngeal squamous cell carcinoma
Metrics: PDF 514 views | Full Text 590 views | ?
Alexander K. Verma1, Shanta M. Messerli1 and W. Keith Miskimins1
1 Cancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, SD, USA
|W. Keith Miskimins,||email:||Keith.Miskimins@sanfordhealth.org|
Keywords: oropharyngeal cancer; lactate; Ras; anti-tumor immunity; PD-L1
Received: January 10, 2019 Accepted: November 13, 2019 Published: April 28, 2020
Intratumoral lactate production negatively correlates with survival and tumor clearance in the setting of human papillomavirus positive oropharyngeal squamous cell carcinoma (HPV-positive OPSCC). Robust anti-tumor immune activity is required for tumor clearance in human patients and animal models of this disease, and intratumoral lactate interferes with this process. While lactate is known to directly inhibit T cell activity, recent evidence has demonstrated that lactate can affect gene expression in multiple cell types. We therefore sought to determine if lactate in the tumor microenvironment could aid immune evasion by inducing the expression of immune checkpoint co-inhibitors. Using a mouse cell line transformed with HPV16 E6, E7, and HRASG12V, we determined that OPSCC cells carrying the HRASG12V mutant showed significantly increased expression of PD-L1 in the presence of extracellular lactate. Furthermore, we demonstrate here that lactate activates the MEK/ERK pathway in Ras-mutated cells.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.